Pfizer pins post 2028 return to growth on new obesity and cancer drugs

Pfizer reported first-quarter sales of $14.45 billion, topping the $13.79 billion estimate, while adjusted EPS of 75 cents beat consensus by 3 cents. The company kept full-year guidance unchanged at $59.5 billion-$62.5 billion in revenue and $2.80-$3.00 EPS, but highlighted support from Eliquis, Padcev and Nurtec ODT and longer-term upside from obesity drugs, Vyndamax patent protection through mid-2031, and a favorable European COVID vaccine ruling. Near-term shares were little changed, suggesting the results were solid but not enough to trigger a major rerating.

Analysis

The market is still treating PFE like a melting-ice-cube cash cow, but the more important shift is that the company is trying to convert a sequence of idiosyncratic assets into a multi-year earnings bridge. The near-term outperformance from newer products matters less for this quarter than for what it does to terminal value: it reduces the odds that the post-2028 trough is as deep as the sell-side has modeled. That said, management’s confidence is not yet self-funded by pipeline de-risking, so the equity remains hostage to a catalyst cadence rather than to durable multiple expansion.

The biggest second-order effect is on the competitive set. If Pfizer can keep its physician access and commercial infrastructure monetized into obesity, adult pneumococcal, and ex-U.S. primary care, smaller biotech obesity entrants may face a tougher launch environment than headline market size implies. The real wedge is not just R&D success; it is distribution. That favors incumbents with broad sales coverage and emerging-market reach, and it likely compresses the premium investors are willing to pay for standalone obesity stories without reimbursement or commercial proof.

BNTX is more of a hidden loser here than the headline suggests. Any legal or contractual win that stabilizes COVID-related cash flow is supportive, but it also risks keeping the market anchored to a declining legacy franchise rather than forcing a cleaner sum-of-the-parts rerating. The contrarian read is that the stock may be underpricing the value of patent extensions and litigation resolution because the market is still anchoring to the ex-COVID earnings decay, which makes setup attractive for a medium-horizon re-rating if sequential pipeline readouts stay constructive.

The main risk is timing: the equity can drift for months if obesity data slip, Vyndamax assumptions prove too aggressive, or the European vaccine payment becomes a one-off rather than a repeatable enforcement template. If the next 1-2 clinical updates disappoint, the market will likely re-focus on 2026-2028 erosion and ignore the longer-dated growth bridge. Until then, this is a conditional rerate story with downside cushioned by cash generation but upside gated by proof.

Key Decisions for Investors

• Long PFE on a 3-6 month horizon, sized as a catalyst basket position rather than a core hold; risk/reward improves if the market is underestimating patent-extension durability and ex-COVID commercial stabilization.
• Buy PFE Jan-2027 calls or call spreads to express the post-2028 re-rating thesis; limited downside, attractive convexity if pipeline data and obesity progress continue to de-risk over the next 12-18 months.
• Pair long PFE / short a basket of lower-quality biotech obesity proxies over 6-12 months; thesis is that commercial scale and physician access matter more than pure-play narrative once data normalizes.
• For event-driven accounts, add BNTX on weakness only if you want litigation/cash-flow optionality; otherwise avoid outright long exposure until there is visibility that legal wins translate into recurring economics.